MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy.

about

MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy.

Item

http://www.wikidata.org/entity/Q50054492

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

MHC Intratumoral Heterogeneity ...... and Response to Immunotherapy.

@en

MHC Intratumoral Heterogeneity ...... and Response to Immunotherapy.

@nl

type

Item

label

MHC Intratumoral Heterogeneity ...... and Response to Immunotherapy.

@en

MHC Intratumoral Heterogeneity ...... and Response to Immunotherapy.

@nl

prefLabel

MHC Intratumoral Heterogeneity ...... and Response to Immunotherapy.

@en

MHC Intratumoral Heterogeneity ...... and Response to Immunotherapy.

@nl

P1476

MHC Intratumoral Heterogeneity ...... and Response to Immunotherapy

@en

P2093

Antonia Collado

http://www.w3.org/2001/XMLSchema#string

Cristina Garrido

http://www.w3.org/2001/XMLSchema#string

Federico Garrido

http://www.w3.org/2001/XMLSchema#string

Ignacio Algarra

http://www.w3.org/2001/XMLSchema#string

Irene Romero

http://www.w3.org/2001/XMLSchema#string

Virginia Chamorro

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer genome landscapes

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

The urgent need to recover MHC class I in cancers for effective immunotherapy

Systemic spread is an early step in breast cancer

Early dissemination seeds metastasis in breast cancer.

Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma.

Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells

The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells.

Prognostic value of HLA class I expression in patients with colorectal cancer.

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape

P304

102

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FIMMU.2018.00102

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Angel Garcia-Lora

P577

2018-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29434605

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

5796886

http://www.w3.org/2001/XMLSchema#string